Relay Therapeutics (RLAY) Earnings Date & Reports

Key Takeaways

• Relay Therapeutics is expected to report third-quarter 2026 results on Thursday, November 5, 2026, after the market close.
• Wall Street consensus calls for a net loss of roughly $0.40 per share, on revenue of about $1.62 million.
• The company is a clinical-stage biotech, so investors will focus less on the top line and more on pipeline updates and cash runway.
• Last quarter, Relay posted a loss of $0.41 per share on just $0.35 million in revenue, missing revenue estimates.
• Key watch items include clinical progress for lead candidate Zovegalisib and spending trends across research and development.

Earnings Context and Why It Matters

Relay Therapeutics, Inc. (RLAY) is a precision-medicine company developing therapies for cancer and genetic diseases. Because most of its programs are still in clinical testing, quarterly revenue is minimal, and the company routinely reports a net loss. For this reason, investors tend to read Relay's earnings as a checkpoint on execution rather than profitability. The upcoming print follows a second quarter in which revenue came in well below expectations, making the third-quarter report an opportunity to gauge whether spending discipline and clinical momentum remain on track heading into 2027.

Earnings Expectations

For the third quarter of 2026, the consensus estimate calls for a net loss of approximately $0.40 per share (EPS, or earnings per share), with revenue of about $1.62 million, according to analyst data compiled by firms such as Zacks Investment Research and MarketBeat. These figures should be treated as Wall Street expectations rather than company guidance, as Relay does not typically provide quarterly financial guidance.

For context, in the same period a year earlier, Relay reported a net loss of $0.43 per share with effectively no revenue. In the most recent quarter ended June 30, 2026, the company posted a loss of $0.41 per share on roughly $0.35 million in revenue, both below consensus at the time. The stock has historically shown moderate post-earnings volatility, with one data provider noting a roughly 4.8% post-announcement drift following the August 2026 release.

Investors will also watch operating expenses closely, particularly research and development (R&D) costs, which totaled $70.6 million in the first quarter of 2026, as well as the company's cash position. Relay ended the first quarter with approximately $642.1 million in cash, cash equivalents, and investments, which management has said is sufficient to fund operations into 2029.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors following names like Relay Therapeutics, it can surface comparable biotech setups and momentum signals across the broader market.

Market Reaction and Investor Sentiment

Heading into the November 5 report, sentiment around Relay Therapeutics appears balanced between optimism about its pipeline and caution over recurring revenue misses. The lead asset, Zovegalisib, a first-in-class, pan-mutant selective PI3Kα (phosphoinositide 3-kinase alpha) inhibitor, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in a breast cancer setting, which has supported the investment thesis. At the same time, the stock has shown sensitivity to quarterly revenue shortfalls, and analysts trimmed 2026 revenue estimates following the first-quarter report earlier in the year. Key risk factors include trial timelines, data readouts, and the pace of R&D spending.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, investors will likely focus on several pipeline milestones rather than near-term financials. Relay plans to begin a Phase 3 frontline study of Zovegalisib in endocrine-sensitive metastatic breast cancer in early 2027, with Pfizer supplying companion therapies. Progress toward that initiation is a central catalyst.

The company has also advanced its triplet combination of Zovegalisib, atirmociclib, and endocrine therapy, reporting a 44% objective response rate in heavily pre-treated patients. Continued data updates in this program could shape sentiment well before any revenue contribution materializes.

Separately, Relay recently began a Phase 1/2 trial of RLY-8161, its NRAS-selective inhibitor, in NRAS-mutated solid tumors, while its aGal program for Fabry disease remains in preclinical development. Because these programs are early-stage, investors should watch enrollment progress and any early safety or efficacy signals.

Finally, cash management remains a critical metric. With a runway expected to last into 2029, the key question is whether R&D spending stays disciplined as clinical activity accelerates. Any commentary on the pace of trial enrollment, partnership economics, or future financing plans will be closely watched.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations